EDMONTON, ALBERTA -- (Marketwire) -- 12/04/12 -- Innovotech Inc. (TSX VENTURE:IOT) intends to complete an offering in order to capitalize on the introduction of its novel antimicrobial technology to address hospital-acquired infections (HAI).

HAI's cause 99,000 fatalities annually in the US, at a cost of $33 billion to the healthcare system. The primary cause is attributed to the use of medical devices particularly blood and urinary catheters and tubes to assist breathing.

Innovotech has developed a novel antimicrobial compound that possesses unique properties making it ideal for coating medical devices to control HAI's.

Innovotech is very familiar with this field as its contract research business develops scientific studies for medical device companies to support claims for antimicrobial coatings. The company has Material Transfer Agreements in place with three companies who have expressed interest in the compound.

The offering, subject to regulatory approval, is comprised of up to 1,666,667 units ("Units") at a price of $0.30 per Unit for gross proceeds of up to $500,000 by way of a private placement (the "Offering"). Each Unit is comprised of one (1) common share ("Common Share") and one (1) Common Share purchase warrant ("Warrant"). Each Warrant entitles the holder to purchase one (1) additional Common Share at a price of $0.40 per Common Share for a period of three (3) years following the date of closing.

About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are organized communities of microorganisms that exist in virtually every natural environment and are responsible for a host of diseases in human health, animal health and agriculture. There are few products or regulatory standards, aside from those of Innovotech, designed specifically for biofilm-forming organisms.

Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including commercially available products in three market segments; the MBEC Assay(TM), bioFILM PA(TM), InnovoSCEPT-Human and InnovoSCEPT-Veterinary tests. The MBEC Assay(TM) is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA(TM) and InnovoSCEPT-Human are the first diagnostic tests to assist physicians in the selection of the most effective antibiotic treatment for patients with biofilm-based chronic infections, while the InnovoSCEPT veterinary tests are designed to determine the most effective antibiotic treatment for chronic infections in both large and small animals.

Innovotech also has three products in advanced stages of development; Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections, AgreGuard(TM) is a unique antimicrobial for coating medical devices such as catheters, and SaniLux(TM) is a light-activated, natural hard surface sanitizer.

Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter: www.twitter.com/innovotech

Facebook: www.facebook.com/innovotech

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.